Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sarepta's new CEO Michael Severino faces critical milestones to prove growth

6 August 2026 · By · Wire by Fusion42

Published

6 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 30 August 2026 · Fusion42 review

Sarepta's new CEO Michael Severino faces critical regulatory and commercial milestones in 2026-27 related to its Duchenne muscular dystrophy franchise, including FDA decisions on key therapies Elevidys, Vyondys 53, and Amondys 45, alongside competitive threats and upcoming siRNA program readouts.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a narrowing window as key FDA decisions and competitive pressure will reshape your Duchenne muscular dystrophy drug sales and R&D focus this year. Time to engage payers and doctors hard now to secure demand before data and approvals define the next growth phase.

◆ Coverage

1 source · 6 Aug 2026

◆ Related on Wire

◆ Topics

Biotechduchenne-muscular-dystrophyfda-approvalgene-therapyexon-skippingsiRNArare-disease